Finland· FI-REL-REL29516
Confidex
A coagulation factor ix, ii, vii and x in combination product containing human coagulation factor ii + human coagulation factor iii + human coagulation factor ix + human coagulation factor x + 2 more, registered in Finland by CSL Behring GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor ix, ii, vii and x in combination is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD01 (coagulation factor ix, ii, vii and x in combination), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor ix, ii, vii and x in combination · ATC B02BD01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Human coagulation factor II + Human coagulation factor III + Human coagulation factor IX + Human coagulation factor X + 2 more
- Manufacturer
- CSL Behring GmbH
- Country
- Finland (FI)
- ATC code
- B02BD01
- ATC class
- Coagulation factor IX, II, VII and X in combination
- Defined daily dose
- 1.6 TSD, E
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for coagulation factor ix, ii, vii and x in combination.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor ix, ii, vii and x in combination · interactions on record
3 records
- 2 severe
- 1 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B02BD01
Coagulation factor ix, ii, vii and x in combination, as other registers publish it.
- CzechiaBERIPLEXCSL Behring GmbH, Marburg
- CzechiaBERIPLEXCSL Behring GmbH, Marburg
- SwitzerlandBeriplex P/N 1000
- PolandBeriplex P/N 1000CSL Behring GmbH
- CanadaBERIPLEX P/N 1000CSL BEHRING CANADA INC
- NetherlandsBeriplex P/N 1000 IE, poeder en oplosmiddel voor oplossing voor injectieCSL Behring GmbH
- IrelandBeriplex P/N 1000 IU, powder and solvent for solution for injectionCSL Behring GmbH
- SwitzerlandBeriplex P/N 1000, Pulver und Lösungsmittel zur Herstellung einer InjektionslösungCSL Behring AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f1b62543-e0e1-4f87-b609-75e38e2c26eb GET /v1/drugs/f1b62543-e0e1-4f87-b609-75e38e2c26eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "500 IU",
"atc_label": "hyytymistekijät IX, II, VII ja X yhdistelmävalmisteina",
"ma_number": "24125",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL29516",
"authorised_at": "2008-05-05"
}See everything about coagulation factor ix, ii, vii and x in combination.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.